Kojic acid (Synonyms: 曲酸)

目录号: HY-W050154 纯度: 99.99%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Kojic acid 是由 Aspergillus oryzae 产生的物质，具有口服有效性，也可被透皮吸收。Kojic acid 具有抗衰老、抗线虫、抗菌、抗氧化、抗炎等多种生物活性。Kojic acid 是Tyrosinase抑制剂，对 Mushroon Tyrosinase IC₅₀ 为 182.7 μM。Kojic acid 通过捕获与酪氨酸酶活性位点结合的铜离子防止其激活来阻止黑色素产生。Kojic acid 对人角质形成细胞中 NF-κB 和 p21 信号通路具有抑制作用。Kojic acid 衍生物具有抗肿瘤活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Kojic acid Chemical Structure

CAS No. : 501-30-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
1 g	￥200	In-stock
5 g	￥400	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Kojic acid:

Kojic acid-¹³C₆ 询价
Kojic acid (Standard) 询价

Kojic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

查看 NF-κB 亚型特异性产品:

查看所有亚型

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

查看 CDK 亚型特异性产品:

查看所有亚型

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85

生物活性
纯度 & 产品资料
参考文献

生物活性

Kojic acid is a substance produced by Aspergillus oryzae that is orally effective and can also be absorbed transdermally. Kojic acid exhibits various biological activities, including anti-aging, anti-nematode, antimicrobial, antioxidant, and anti-inflammatory effects. Kojic acid is a Tyrosinase inhibitor with an Mushroom Tyrosinase IC₅₀ of 182.7 μM. Kojic acid prevents melanin production by capturing copper ions that bind to the tyrosinase active site, thus inhibiting its activation. Kojic acid also suppresses the NF-κB and p21 signaling pathways in human keratinocytes. Kojic acid derivatives have anticancer activity^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	GI₅₀	> 100 μM Compound: 1; KA	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 35114540]
B16	IC₅₀	> 50 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 48 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 48 hrs	[PMID: 20149498]
B16	IC₅₀	> 500 μM Compound: Kojic acid	Inhibition of alpha-MSH-stimulated melanin production in mouse B16 cells after 72 hrs by microplate reader analysis Inhibition of alpha-MSH-stimulated melanin production in mouse B16 cells after 72 hrs by microplate reader analysis	[PMID: 26706112]
B16	IC₅₀	111 μM Compound: Kojic acid	Antimelanogenic activity in mouse B16 cells assessed as inhibition of intracellular melanin accumulation after 2 days Antimelanogenic activity in mouse B16 cells assessed as inhibition of intracellular melanin accumulation after 2 days	[PMID: 19524439]
B16	IC₅₀	15.8 μM Compound: Kojic acid	Inhibition of alpha-MSH -stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs by spectrometric analysis Inhibition of alpha-MSH -stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs by spectrometric analysis	[PMID: 21978680]
B16	IC₅₀	39 μM Compound: Kojic acid	Inhibition of melanin production in alpha-MSH stimulated mouse B16 cells after 72 hrs by spectrophotometry Inhibition of melanin production in alpha-MSH stimulated mouse B16 cells after 72 hrs by spectrophotometry	[PMID: 23623417]
B16	IC₅₀	5.5 μg/mL Compound: Kojic acid	Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs Inhibition of alpha-MSH-stimulated melanogenesis in mouse B16 cells assessed as melanin release after 72 hrs	[PMID: 22450129]
B16	IC₅₀	70 μM Compound: Kojic acid	Antimelanogenic activity at alpha-MSH-stimulated mouse melanoma B16 cells after 3 days by spectrophotometry Antimelanogenic activity at alpha-MSH-stimulated mouse melanoma B16 cells after 3 days by spectrophotometry	[PMID: 22217872]
B16	IC₅₀	70 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 3 days Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 3 days	[PMID: 21601449]
B16	IC₅₀	70 μM Compound: kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs	[PMID: 20097083]
B16	IC₅₀	70 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs Inhibition of alpha-MSH-induced melanin production in mouse B16 cells after 72 hrs	[PMID: 20044259]
B16-F10	IC₅₀	144.4 μM Compound: 1a; KA	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability by MTT assay	[PMID: 32652434]
B16-F10	IC₅₀	500 μM Compound: Kojic acid	Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days Antimelanogenic activity in mouse B16F10 cells assessed as inhibition of melanin production after 4 days	[PMID: 25597012]
B16-F10	IC₅₀	84.54 μM Compound: Kojic acid	Inhibition of alpha-MSH-induced melanogenesis in mouse B16F10 cells after 3 days by spectrophotometric analysis Inhibition of alpha-MSH-induced melanogenesis in mouse B16F10 cells after 3 days by spectrophotometric analysis	[PMID: 23063404]
BV-2	IC₅₀	> 500 μM Compound: KA	Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse BV-2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
G-361	IC₅₀	571.17 μM Compound: Kojic acid	Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry Competitive inhibition of tyrosinase in human G-361 cells incubated for 10 mins measured for 2 hrs by MBTH-based spectrophotometry	[PMID: 25288494]
H9c2	IC₅₀	> 500 μM Compound: KA	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
HEK293	IC₅₀	2 μM Compound: 6a, Kojic acid	Inhibition of human recombinant DAAO expressed in HEK293 cell lysate assessed as D-Serine conversion to H2O2 after 20 mins by spectrophotometric analysis Inhibition of human recombinant DAAO expressed in HEK293 cell lysate assessed as D-Serine conversion to H2O2 after 20 mins by spectrophotometric analysis	[PMID: 23683589]
HFF	IC₅₀	> 150 μM Compound: 1a; KA	Cytotoxicity against human HFF cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability by MTT assay	[PMID: 32652434]
HT-22	IC₅₀	> 500 μM Compound: KA	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
L02	IC₅₀	> 500 μM Compound: KA	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]
Melan-a	IC₅₀	1.6 mM Compound: 1	Depigmentation activity in mouse Melan-a cells assessed as inhibition of melanin formation after 4 days Depigmentation activity in mouse Melan-a cells assessed as inhibition of melanin formation after 4 days	[PMID: 22071299]
Melan-a	IC₅₀	1.64 mM Compound: 1, Kojic acid	Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry	[PMID: 22579419]
Melan-a	IC₅₀	3.5 mM Compound: 1	Cytotoxicity against mouse Melan-a cells by modified crystal voilet assay Cytotoxicity against mouse Melan-a cells by modified crystal voilet assay	[PMID: 22071299]
Melan-a	IC₅₀	3.53 mM Compound: 1, Kojic acid	Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method	[PMID: 22579419]
RAW264.7	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 20934336]
RAW264.7	IC₅₀	89.41 μM Compound: 1	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated for 30 mins before LPS challenge measured after 24 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated for 30 mins before LPS challenge measured after 24 hrs by Griess reagent method	[PMID: 20934336]
SH-SY5Y	IC₅₀	> 500 μM Compound: KA	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36846369]

体外研究
(In Vitro)

Kojic acid (1000 μM，7 天) 增强 HCEC 细胞的细胞迁移能力，并对其具有抗衰老活性^[1]。
Kojic acid (1000 μM, 7 天) 可能通过 NF-κB 和 p21 信号通路缓解由衰老的 HCEC 细胞的上清液诱导的人脐静脉内皮细胞 (HUVEC) 血管生成^[1]。
Kojic acid (1.4-1000 μg/mL，3天) 对 M. incognita 表现出剂量依赖性的致死率和孵化抑制率，EC₅₀ 分别为 195.2 μg/mL 和 238.3 μg/mL^[4]。
Kojic acid (1000 μM，2-6 天) 以浓度依赖的方式抑制 B16-4A5 细胞和 HMV-II 细胞中的黑色素生成^[6]。
Kojic acid (500 或 1000 µM，72 小时) 降低了 B16-4A5 细胞 HMV-II 细胞中和酪氨酸酶表达，表明 Kojic acid 由于抑制酪氨酸酶活性而抑制黑色素生成^[6]。
Kojic acid (10-2500 μM，7 天) 对 HCEC 细胞活力无显著影响^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:	10, 100 , 1000, 2500, 5000 μM
Incubation Time:	7 days
Result:	Did not influence the cell viability of HCEC after 7 days' treatment at 10-2500 μM but decreased the cell viability a little bit at 5000 μM.

Cell Migration Assay ^[1]

Cell Line:	HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:	1000 μM
Incubation Time:	7 days
Result:	Delayed the reduction in cell migration ability caused by aging in HCEC cells.

Western Blot Analysis^[1]

Cell Line:	HCEC-B4G12 cells (human corneal endothelial cell line)
Concentration:	1000 μM
Incubation Time:	7 days
Result:	Inhibited the abnormal high expression of galectin 8, laminin α1, laminin α2, laminin γ1, and p21 in senescent HCEC, as well as the significant decrease in p-NF-κB protein expression.

体内研究
(In Vivo)

Kojic acid (50 mg/kg，口服，1 天 1 次连续 3 周) 对 β-Amyloid (1-42), human (HY-P1363A) 诱导的阿尔兹海默症小鼠模型具有抗氧化和抗炎活性^[8]。
Kojic acid (4, 6.4, 10, 16 g/kg, 口服, 单次给药) 在急性口服实验中对 JCL-Wistar 大鼠的毒性较小^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	β-Amyloid (1-42), human (HY-P1363A)-Induced Mouse Model of Alzheimer's Disease^[8]
Dosage:	50 mg/kg
Administration:	Oral gavage, once daily for 3 weeks
Result:	Ameliorated β-Amyloid (1-42), human (HY-P1363A)-induced glial cell activation and reduced inflammatory markers in the hippocampus. Reduced ROS and lipid peroxidase levels in Alzheimer's Disease mice model

Animal Model:	JCL-Wistar rats^[2]
Dosage:	4, 6.4, 10, 16 g/kg
Administration:	Oral gavage (p.o.),single dose
Result:	Had an oral LD50 in rats greater than 2 g/kg in acute toxicity studies^[2].

分子量

142.11

Formula

C₆H₆O₄

CAS 号

501-30-4

性状

固体

颜色

Off-white to light yellow

中文名称

曲酸

结构分类

Ketones, Aldehydes, Acids

初始来源

微生物

Aspergillus, Penicillium or Acetobacter spp

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (703.68 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 50 mg/mL (351.84 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	7.0368 mL	35.1840 mL	70.3680 mL
5 mM	1.4074 mL	7.0368 mL	14.0736 mL
10 mM	0.7037 mL	3.5184 mL	7.0368 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (35.18 mM); 悬浊液; 超声助溶

此方案可获得 5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (17.59 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (17.59 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 14.29 mg/mL (100.56 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

该产品水溶性佳，请具体参考实测水 / PBS / Saline 中的溶解度数据。

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.99%

选择批次：

Data Sheet (655 KB) SDS (556 KB)

COA (284 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Wei X, et al. Kojic acid inhibits senescence of human corneal endothelial cells via NF-κB and p21 signaling pathways. Exp Eye Res. 2018 Dec 28;180:174-183. [Content Brief]

[2]. Burnett C L, et al. Final report of the safety assessment of kojic acid as used in cosmetics[J]. International journal of toxicology, 2010, 29(6_suppl): 244S-273S. [Content Brief]

[3]. Saeedi M, et al. Kojic acid applications in cosmetic and pharmaceutical preparations. Biomed Pharmacother. 2019 Feb;110:582-593. doi: 10.1016/j.biopha.2018.12.006. [Content Brief]

[4]. Kim T Y, et al. Nematicidal activity of kojic acid produced by Aspergillus oryzae against Meloidogyne incognita[J]. Journal of Microbiology and Biotechnology, 2016, 26(8): 1383-1391. [Content Brief]

[5]. Zilles J C, et al. Biological activities and safety data of kojic acid and its derivatives: A review[J]. Experimental dermatology, 2022, 31(10): 1500-1521. [Content Brief]

[6]. Kai H, et al. Assessment of the effect of arbutin isomers and kojic acid on melanin production, tyrosinase activity, and tyrosinase expression in B16-4A5 and HMV-II melanoma cells[J]. Planta Medica Letters, 2015, 2(01): e39-e41.

[7]. Karakaya G, et al. Synthesis and cytotoxic evaluation of kojic acid derivatives with inhibitory activity on melanogenesis in human melanoma cells[J]. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2018, 18(15): 2137-2148. [Content Brief]

[8]. Khan A, et al. Antioxidative and Anti-inflammatory Effects of Kojic Acid in Aβ-Induced Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2021 Oct;58(10):5127-5140. [Content Brief]

Kojic acid 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	7.0368 mL	35.1840 mL	70.3680 mL	175.9201 mL
	5 mM	1.4074 mL	7.0368 mL	14.0736 mL	35.1840 mL
	10 mM	0.7037 mL	3.5184 mL	7.0368 mL	17.5920 mL
	15 mM	0.4691 mL	2.3456 mL	4.6912 mL	11.7280 mL
	20 mM	0.3518 mL	1.7592 mL	3.5184 mL	8.7960 mL
	25 mM	0.2815 mL	1.4074 mL	2.8147 mL	7.0368 mL
	30 mM	0.2346 mL	1.1728 mL	2.3456 mL	5.8640 mL
	40 mM	0.1759 mL	0.8796 mL	1.7592 mL	4.3980 mL
	50 mM	0.1407 mL	0.7037 mL	1.4074 mL	3.5184 mL
	60 mM	0.1173 mL	0.5864 mL	1.1728 mL	2.9320 mL
	80 mM	0.0880 mL	0.4398 mL	0.8796 mL	2.1990 mL
	100 mM	0.0704 mL	0.3518 mL	0.7037 mL	1.7592 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Kojic acid (Synonyms: 曲酸)

Customer Review

Other Forms of Kojic acid:

Kojic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

查看 CDK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Kojic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Kojic acid (Synonyms: 曲酸)

Customer Review

Other Forms of Kojic acid:

Kojic acid 相关抗体

Kojic acid 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Parasite 亚型特异性产品:

查看 NF-κB 亚型特异性产品:

查看 CDK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Kojic acid 相关抗体:

摩尔计算器

稀释计算器

Kojic acid 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z